Endocrine FGFs and Klothos: emerging concepts

Trends in Endocrinology and Metabolism

Volumn 19, Issue 7, 2008, Pages 239-245

  Kuro o, Makoto ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; CELL NUCLEUS RECEPTOR; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 15; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR 21; FIBROBLAST GROWTH FACTOR 23; ISOPROTEIN; KLOTHO PROTEIN; PHOSPHATE; PROTEIN SUBUNIT; VITAMIN D;

ADIPOCYTE; BILE ACID SYNTHESIS; BINDING AFFINITY; BIOSYNTHESIS; ENDOCRINE SYSTEM; FEEDBACK SYSTEM; GENE IDENTIFICATION; GLUCOSE TRANSPORT; HUMAN; MULTIGENE FAMILY; NONHUMAN; PARATHYROID GLAND; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TISSUE DISTRIBUTION;

ANIMALS; ENDOCRINE SYSTEM; FIBROBLAST GROWTH FACTORS; GLUCURONIDASE; HUMANS; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 49649118142     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2008.06.002     Document Type: Review

References (64)

1. Thisse B., and Thisse C. Functions and regulations of fibroblast growth factor signaling during embryonic development. Dev. Biol. 287 (2005) 390-402
2. Bottcher R.T., and Niehrs C. Fibroblast growth factor signaling during early vertebrate development. Endocr. Rev. 26 (2005) 63-77
3. Itoh N., and Ornitz D.M. Evolution of the Fgf and Fgfr gene families. Trends Genet. 20 (2004) 563-569
4. Mohammadi M., et al. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev. 16 (2005) 107-137
5. Itoh N., and Ornitz D.M. Functional evolutionary history of the mouse Fgf gene family. Dev. Dyn. 237 (2008) 18-27
6. ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat. Genet. 26 (2000) 345-348
7. Liu S., et al. Pathogenic role of Fgf23 in Hyp mice. Am. J. Physiol. Endocrinol. Metab. 291 (2006) E38-E49
8. Shimada T., et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 6500-6505
9. Shimada T., et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J. Bone Miner. Res. 19 (2004) 429-435
10. Urakawa I., et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444 (2006) 770-774
11. Imanishi Y., et al. FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int. 65 (2004) 1943-1946
12. White K.E., et al. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int. 60 (2001) 2079-2086
13. Quarles L.D. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization. Am. J. Physiol. Endocrinol. Metab. 285 (2003) E1-E9
14. Yu X., et al. Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology 146 (2005) 4647-4656
15. Kuro-o M., et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390 (1997) 45-51
16. Yamamoto M., et al. Regulation of oxidative stress by the anti-aging hormone Klotho. J. Biol. Chem. 280 (2005) 38029-38034
17. Kurosu H., et al. Suppression of aging in mice by the hormone Klotho. Science 309 (2005) 1829-1833
18. Kurosu H., et al. Regulation of fibroblast growth factor-23 signaling by Klotho. J. Biol. Chem. 281 (2006) 6120-6123
19. Shimada T., et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J. Clin. Invest. 113 (2004) 561-568
20. Razzaque M.S., et al. Premature aging-like phenotype in fibroblast growth factor 23 null mice is a vitamin D-mediated process. FASEB J. 20 (2006) 720-722
21. Yoshida T., et al. Mediation of unusually high concentrations of 1,25-dihydroxyvitamin D in homozygous klotho mutant mice by increased expression of renal 1alpha-hydroxylase gene. Endocrinology 143 (2002) 683-689
22. Kuro-o M. Klotho as a regulator of fibroblast growth factor signaling and phosphate/calcium metabolism. Curr. Opin. Nephrol. Hypertens. 15 (2006) 437-441
23. Ichikawa S., et al. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J. Clin. Invest. 117 (2007) 2684-2691
24. Morishita K., et al. The progression of aging in klotho mutant mice can be modified by dietary phosphorus and zinc. J. Nutr. 131 (2001) 3182-3188
25. Hesse M., et al. Ablation of vitamin D signaling rescues bone, mineral, and glucose homeostasis in Fgf-23 deficient mice. Matrix Biol. 26 (2007) 75-84
26. Stubbs J.R., et al. Role of Hyperphosphatemia and 1,25-Dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J. Am. Soc. Nephrol. 18 (2007) 2116-2124
27. Imura A., et al. alpha-Klotho as a regulator of calcium homeostasis. Science 316 (2007) 1615-1618
28. Hofer A.M., and Brown E.M. Extracellular calcium sensing and signalling. Nat. Rev. Mol. Cell Biol. 4 (2003) 530-538
29. Dusso A.S., et al. Vitamin D. Am. J. Physiol. Renal Physiol. 289 (2005) F8-F28
30. Berndt T., and Kumar R. Phosphatonins and the regulation of phosphate homeostasis. Annu. Rev. Physiol. 69 (2007) 341-359
31. Ben-Dov I.Z., et al. The parathyroid is a target organ for FGF23 in rats. J. Clin. Invest. 117 (2007) 4003-4008
32. Inagaki T., et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2 (2005) 217-225
33. Choi M., et al. Identification of a hormonal basis for gallbladder filling. Nat. Med. 12 (2006) 1253-1255
34. Yu C., et al. Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4. J. Biol. Chem. 275 (2000) 15482-15489
35. Ito S., et al. Molecular cloning and expression analyses of mouse betaklotho, which encodes a novel Klotho family protein. Mech. Dev. 98 (2000) 115-119
36. Ito S., et al. Impaired negative feedback suppression of bile acid synthesis in mice lacking betaKlotho. J. Clin. Invest. 115 (2005) 2202-2208
37. Kurosu H., et al. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J. Biol. Chem. 282 (2007) 26687-26695
38. Lin B.C., et al. Liver-specific activities of FGF19 require Klotho beta. J. Biol. Chem. 282 (2007) 27277-27284
39. Wu X., et al. Co-receptor requirements for fibroblast growth factor-19 signaling. J. Biol. Chem. 282 (2007) 29069-29072
40. Kharitonenkov A., et al. FGF-21 as a novel metabolic regulator. J. Clin. Invest. 115 (2005) 1627-1635
41. Pessin J.E., and Bell G.I. Mammalian facilitative glucose transporter family: structure and molecular regulation. Annu. Rev. Physiol. 54 (1992) 911-930
42. Inagaki T., et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab. 5 (2007) 415-425
43. Ogawa Y., et al. betaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 7432-7437
44. Kharitonenkov A., et al. FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho. J. Cell. Physiol. 215 (2008) 1-7
45. Suzuki M., et al. betaKlotho is required for FGF21signaling through FGFR1c and FGFR3c. Mol. Endocrinol. 22 (2008) 1006-1014
46. Yu X., et al. Genetic dissection of phosphate- and vitamin D-mediated regulation of circulating Fgf23 concentrations. Bone 36 (2005) 971-977
47. Bai X.Y., et al. The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J. Biol. Chem. 278 (2003) 9843-9849
48. Tsujikawa H., et al. Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Mol. Endocrinol. 17 (2003) 2393-2403
49. Goodwin B., et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol. Cell 6 (2000) 517-526
50. Lu T.T., et al. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol. Cell 6 (2000) 507-515
51. Kalaany N.Y., and Mangelsdorf D.J. LXRS and FXR: the yin and yang of cholesterol and fat metabolism. Annu. Rev. Physiol. 68 (2006) 159-191
52. Kuipers F., et al. Bile acids, farnesoid X receptor, atherosclerosis and metabolic control. Curr. Opin. Lipidol. 18 (2007) 289-297
53. Badman M.K., et al. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 5 (2007) 426-437
54. Lefebvre P., et al. Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J. Clin. Invest. 116 (2006) 571-580
55. Kersten S., et al. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J. Clin. Invest. 103 (1999) 1489-1498
56. Kersten S., et al. Roles of PPARs in health and disease. Nature 405 (2000) 421-424
57. Moore D.D. Physiology. Sister act. Science 316 (2007) 1436-1438
58. Matsumura Y., et al. Identification of the human klotho gene and its two transcripts encoding membrane and secreted klotho protein. Biochem. Biophys. Res. Commun. 242 (1998) 626-630
59. Zhang X., et al. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J. Biol. Chem. 281 (2006) 15694-15700
60. Givol D., and Yayon A. Complexity of FGF receptors: genetic basis for structural diversity and functional specificity. FASEB J. 6 (1992) 3362-3369
61. Kostrzewa M., and Muller U. Genomic structure and complete sequence of the human FGFR4 gene. Mamm. Genome 9 (1998) 131-135
62. Goetz R., et al. Molecular insights into the Klotho-dependent, endocrine mode of action of FGF19 subfamily members. Mol. Cell. Biol. 27 (2007) 3417-3428
63. Harmer N.J., et al. The crystal structure of fibroblast growth factor (FGF) 19 reveals novel features of the FGF family and offers a structural basis for its unusual receptor affinity. Biochemistry 43 (2004) 629-640
64. Schlessinger J., et al. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol. Cell 6 (2000) 743-750